
Frankie L. Stinson
Examiner (ID: 8117)
| Most Active Art Unit | 1746 |
| Art Unit(s) | 1792, 1711, 2402, 1746, 2899, 3405, 1743 |
| Total Applications | 3621 |
| Issued Applications | 3013 |
| Pending Applications | 138 |
| Abandoned Applications | 470 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 19373855
[patent_doc_number] => 12065404
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-08-20
[patent_title] => C4-carboxylic acid-substituted tryptamine derivatives and methods of using
[patent_app_type] => utility
[patent_app_number] => 17/886075
[patent_app_country] => US
[patent_app_date] => 2022-08-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 73
[patent_figures_cnt] => 93
[patent_no_of_words] => 40289
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 50
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17886075
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/886075 | C4-carboxylic acid-substituted tryptamine derivatives and methods of using | Aug 10, 2022 | Issued |
Array
(
[id] => 18077251
[patent_doc_number] => 20220402863
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-22
[patent_title] => NEURO-ATTENUATING KETAMINE AND NORKETAMINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS
[patent_app_type] => utility
[patent_app_number] => 17/882046
[patent_app_country] => US
[patent_app_date] => 2022-08-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27620
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17882046
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/882046 | Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods | Aug 4, 2022 | Issued |
Array
(
[id] => 18077229
[patent_doc_number] => 20220402841
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-22
[patent_title] => Stilbene Derivative and Method for Preparing Same
[patent_app_type] => utility
[patent_app_number] => 17/876138
[patent_app_country] => US
[patent_app_date] => 2022-07-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14402
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 698
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17876138
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/876138 | Stilbene derivative and method for preparing same | Jul 27, 2022 | Issued |
Array
(
[id] => 18034572
[patent_doc_number] => 20220378787
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-01
[patent_title] => DOSING OF KRAS INHIBITOR FOR TREATMENT OF CANCERS
[patent_app_type] => utility
[patent_app_number] => 17/871178
[patent_app_country] => US
[patent_app_date] => 2022-07-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16364
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -37
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17871178
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/871178 | DOSING OF KRAS INHIBITOR FOR TREATMENT OF CANCERS | Jul 21, 2022 | Abandoned |
Array
(
[id] => 18003405
[patent_doc_number] => 20220362171
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-17
[patent_title] => USE OF TAPINAROF FOR THE TREATMENT OF CHRONIC PLAQUE PSORIASIS
[patent_app_type] => utility
[patent_app_number] => 17/871663
[patent_app_country] => US
[patent_app_date] => 2022-07-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 52741
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 60
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17871663
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/871663 | Use of Tapinarof for the treatment of chronic plaque psoriasis | Jul 21, 2022 | Issued |
Array
(
[id] => 18020542
[patent_doc_number] => 20220372041
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-24
[patent_title] => QUINOXALINE DERIVATIVES
[patent_app_type] => utility
[patent_app_number] => 17/866672
[patent_app_country] => US
[patent_app_date] => 2022-07-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24822
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 536
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17866672
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/866672 | QUINOXALINE DERIVATIVES | Jul 17, 2022 | Pending |
Array
(
[id] => 18019128
[patent_doc_number] => 20220370627
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-24
[patent_title] => COMPOSITIONS AND METHODS FOR TARGETED PROTEIN STABILIZATION BY REDIRECTING ENDOGENOUS DEUBIQUITINASES
[patent_app_type] => utility
[patent_app_number] => 17/864382
[patent_app_country] => US
[patent_app_date] => 2022-07-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5591
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17864382
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/864382 | COMPOSITIONS AND METHODS FOR TARGETED PROTEIN STABILIZATION BY REDIRECTING ENDOGENOUS DEUBIQUITINASES | Jul 12, 2022 | Pending |
Array
(
[id] => 18184627
[patent_doc_number] => 20230045357
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-09
[patent_title] => BIARYLMETHYL HETEROCYCLES
[patent_app_type] => utility
[patent_app_number] => 17/861809
[patent_app_country] => US
[patent_app_date] => 2022-07-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 134693
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17861809
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/861809 | Biarylmethyl heterocycles | Jul 10, 2022 | Issued |
Array
(
[id] => 18215225
[patent_doc_number] => 11590138
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-02-28
[patent_title] => Topical treatment of vitiligo by a jak inhibitor
[patent_app_type] => utility
[patent_app_number] => 17/860884
[patent_app_country] => US
[patent_app_date] => 2022-07-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 64
[patent_figures_cnt] => 64
[patent_no_of_words] => 31414
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 81
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17860884
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/860884 | Topical treatment of vitiligo by a jak inhibitor | Jul 7, 2022 | Issued |
Array
(
[id] => 19840109
[patent_doc_number] => 12252478
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-03-18
[patent_title] => Crystalline forms of N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide
[patent_app_type] => utility
[patent_app_number] => 17/858701
[patent_app_country] => US
[patent_app_date] => 2022-07-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 14
[patent_no_of_words] => 9120
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 80
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17858701
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/858701 | Crystalline forms of N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide | Jul 5, 2022 | Issued |
Array
(
[id] => 19840110
[patent_doc_number] => 12252479
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-03-18
[patent_title] => Crystalline forms OF N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide
[patent_app_type] => utility
[patent_app_number] => 17/858713
[patent_app_country] => US
[patent_app_date] => 2022-07-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 14
[patent_no_of_words] => 9119
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 80
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17858713
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/858713 | Crystalline forms OF N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide | Jul 5, 2022 | Issued |
Array
(
[id] => 19026307
[patent_doc_number] => 11925647
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-03-12
[patent_title] => Theramutein modulators
[patent_app_type] => utility
[patent_app_number] => 17/857478
[patent_app_country] => US
[patent_app_date] => 2022-07-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 13
[patent_no_of_words] => 23869
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 135
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17857478
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/857478 | Theramutein modulators | Jul 4, 2022 | Issued |
Array
(
[id] => 18824354
[patent_doc_number] => 11839617
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-12-12
[patent_title] => Theramutein modulators
[patent_app_type] => utility
[patent_app_number] => 17/857492
[patent_app_country] => US
[patent_app_date] => 2022-07-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 13
[patent_no_of_words] => 23874
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 162
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17857492
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/857492 | Theramutein modulators | Jul 4, 2022 | Issued |
Array
(
[id] => 17944308
[patent_doc_number] => 20220331325
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-20
[patent_title] => JAK1 PATHWAY INHIBITORS FOR THE TREATMENT OF CHRONIC LUNG ALLOGRAFT DYSFUNCTION
[patent_app_type] => utility
[patent_app_number] => 17/854443
[patent_app_country] => US
[patent_app_date] => 2022-06-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12931
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17854443
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/854443 | JAK1 pathway inhibitors for the treatment of chronic lung allograft dysfunction | Jun 29, 2022 | Issued |
Array
(
[id] => 18418620
[patent_doc_number] => 20230173078
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-08
[patent_title] => SMARCA DEGRADERS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/851528
[patent_app_country] => US
[patent_app_date] => 2022-06-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 182870
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17851528
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/851528 | SMARCA DEGRADERS AND USES THEREOF | Jun 27, 2022 | Abandoned |
Array
(
[id] => 19121009
[patent_doc_number] => 11964979
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-04-23
[patent_title] => Camsylate salts of triazolopyrazine derivatives
[patent_app_type] => utility
[patent_app_number] => 17/849784
[patent_app_country] => US
[patent_app_date] => 2022-06-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 46
[patent_figures_cnt] => 63
[patent_no_of_words] => 9908
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 181
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17849784
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/849784 | Camsylate salts of triazolopyrazine derivatives | Jun 26, 2022 | Issued |
Array
(
[id] => 19624087
[patent_doc_number] => 12162891
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-12-10
[patent_title] => Glutamate transporter activators and methods using same
[patent_app_type] => utility
[patent_app_number] => 17/847490
[patent_app_country] => US
[patent_app_date] => 2022-06-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 25
[patent_figures_cnt] => 33
[patent_no_of_words] => 19532
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 555
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17847490
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/847490 | Glutamate transporter activators and methods using same | Jun 22, 2022 | Issued |
Array
(
[id] => 18091257
[patent_doc_number] => 20220409598
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-29
[patent_title] => METHOD OF CONTROLLING BLOOD SUGAR LEVEL AND TREATMENT OF DIABETES AND RELATED CONDITIONS
[patent_app_type] => utility
[patent_app_number] => 17/843587
[patent_app_country] => US
[patent_app_date] => 2022-06-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17117
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17843587
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/843587 | METHOD OF CONTROLLING BLOOD SUGAR LEVEL AND TREATMENT OF DIABETES AND RELATED CONDITIONS | Jun 16, 2022 | Abandoned |
Array
(
[id] => 19104620
[patent_doc_number] => 11957693
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-04-16
[patent_title] => Combination MCL-1 inhibitors with anti-cancer agents
[patent_app_type] => utility
[patent_app_number] => 17/836444
[patent_app_country] => US
[patent_app_date] => 2022-06-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 22010
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 44
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17836444
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/836444 | Combination MCL-1 inhibitors with anti-cancer agents | Jun 8, 2022 | Issued |
Array
(
[id] => 18352302
[patent_doc_number] => 20230140413
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-04
[patent_title] => Compounds and Methods for Treating, Detecting, and Identifying Compounds to Treat Apicomplexan Parasitic Diseases
[patent_app_type] => utility
[patent_app_number] => 17/831049
[patent_app_country] => US
[patent_app_date] => 2022-06-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 44566
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17831049
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/831049 | Compounds and methods for treating, detecting, and identifying compounds to treat apicomplexan parasitic diseases | Jun 1, 2022 | Issued |